Menopause management is an integrated therapy designed to address a range of physiological and psychological symptoms caused by ovarian failure in women. The primary treatment goals include alleviating typical symptoms such as hot flashes, night sweats, and mood swings, while reducing risks of bone loss, cardiovascular disease, and improving quality of life. Treatment strategies usually combine medication, natural therapies, and lifestyle modifications, tailored to individual health conditions and symptom severity.
This approach emphasizes long-term follow-up and risk assessment, especially for postmenopausal women aged 45 to 55. Physicians evaluate whether patients have a history of hysterectomy, family history of breast cancer, or cardiovascular disease to select the safest and most effective treatment methods. The goal is not only symptom relief but also prevention of long-term complications caused by hormonal deficiencies.
The main treatment options include Hormone Replacement Therapy (HRT), plant estrogen supplements, antidepressants, and psychological counseling. HRT involves supplementing estrogen and progestogen to directly compensate for hormones decreased due to ovarian failure, thereby improving vascular reactivity and bone metabolism. Phytoestrogens like soy isoflavones mimic the body's hormonal effects to regulate endocrine function.
Antidepressants such as SSRIs can modulate serotonin transmission, effectively relieving severe night sweats and emotional instability. Psychological counseling, through cognitive-behavioral therapy, helps patients cope with anxiety and sleep disturbances. Each therapy mechanism varies and should be selected based on symptom severity and individual risk factors.
This therapy is suitable for severe menopausal symptoms that significantly impact daily life, such as more than 10 episodes of hot flashes per month, more than 3 episodes of night sweats per week causing sleep disruption, and fracture risks due to decreased bone density. It is also applicable for urogenital symptoms caused by hormonal deficiencies, such as vaginal dryness and urinary incontinence.
Other indications include cardiovascular risks such as decreased HDL cholesterol and blood pressure fluctuations caused by estrogen decline. It is important to note that contraindications must be excluded, such as history of thrombosis or breast cancer, which may necessitate non-hormonal alternatives.
HRT can be administered via oral tablets, transdermal patches, topical creams, or uterine sprays. Oral forms are typically taken once daily, while patches are replaced every 3-4 days. Phytoestrogen supplements are recommended at 30-60 mg daily, with a balanced diet. Patients with intact uterus should also take progestogen to reduce endometrial cancer risk.
Antidepressants usually start at low doses, such as 10 mg of Venlafaxine daily, with adjustments based on response. Psychological therapy is recommended as weekly 60-minute cognitive-behavioral sessions, continuing for 8-12 weeks per course. All dosage adjustments should be monitored by gynecologists or endocrinologists.
Psychological counseling can improve emotional stability, with studies showing a 30% reduction in anxiety diagnoses. Non-hormonal therapies tend to have milder side effects and are suitable for patients with contraindications. Treatment plans can be adjusted to provide personalized medical options.
HRT may increase the risk of thrombosis (by 1-2% annually) and breast cancer (risk increases by 9% after 5 years of use). Transdermal HRT reduces liver metabolism burden compared to oral forms but still carries a risk of endometrial hyperplasia. Some patients may experience immediate side effects such as breast tenderness, headaches, or edema.
Phytoestrogens may cause bloating or diarrhea; high doses require liver function monitoring. Antidepressants may lead to nausea or insomnia, while short-term emotional fluctuations may occur with psychological therapy. Regular health check-ups are necessary to monitor all treatments.
Absolute contraindications include diagnosed breast cancer, active thrombosis, acute liver disease, and severe endometrial hyperplasia. Relative contraindications include uterine fibroids, migraine history, or unexcluded endometrial cancer. Pre-treatment assessments should include pelvic ultrasound, bone density scans, and cardiovascular risk evaluations.
Women on HRT should have uterine thickness and mammograms every 6 months. Those with a history of thrombosis should only use non-oral delivery methods. If symptoms such as leg swelling, unexplained bleeding, or severe headaches occur during treatment, medication should be discontinued immediately and medical attention sought.
HRT may increase bleeding risk when combined with anticoagulants like Warfarin, requiring dose adjustments. Concurrent use with antiepileptic drugs such as Carbamazepine accelerates hormone metabolism, necessitating HRT dose modifications. Soy products combined with HRT may increase overall estrogen exposure, so intake should be controlled.
Herbal kidney-tonifying preparations may interact with HRT; avoid self-medication. Patients undergoing radiation or chemotherapy should inform their physicians, as treatment intervals may affect efficacy. All concomitant medications should be reviewed thoroughly before starting therapy.
Large randomized controlled trials show that HRT can reduce vertebral fracture risk by 30-50%, with optimal effects within 10 years post-menopause. Cochrane reviews indicate SSRIs have a 60-70% efficacy in relieving night sweats. Phytoestrogen supplementation can increase bone mineral density by 1.5-2.5% and reduce severity of menopausal symptoms by 20-30%.
Meta-analyses of psychological therapies show CBT can reduce anxiety symptoms by 40%, and exercise interventions maintain bone density better than medication. Long-term follow-up studies suggest that individualized treatment plans can improve quality of life scores by 25-35%, but strict duration control is necessary to minimize long-term risks.
Non-hormonal options include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and 5-alpha-reductase inhibitors. Phytotherapy includes black cohosh, cereal estrogens, and evening primrose oil. Physical therapies such as low-dose electrical stimulation have been shown to improve bone density.
Traditional Chinese medicine approaches include kidney-tonifying and blood-activating formulas and acupuncture, which have been shown to alleviate 50% of symptoms. Bioidentical hormones are marketed as "natural" therapies, but their long-term safety remains uncertain. All alternative therapies should be used after evaluation by a healthcare professional.
HRT should be initiated based on individual symptom severity and health status, typically during the early menopausal phase when symptoms are prominent. Dosages should start low and be gradually adjusted according to symptom improvement and side effects, with regular blood tests to monitor estrogen levels to ensure safety and efficacy.
How can non-pharmacological treatments like acupuncture or exercise be effectively combined with medication?Acupuncture and exercise can serve as adjuncts to medication therapy, recommended under medical supervision. For example, acupuncture can help alleviate mood swings, and exercise can improve bone density and sleep quality. Timing and interaction with medication effects should be considered, avoiding overexertion or improper acupoint selection. It is advised to perform aerobic exercise at least 3 times per week for a minimum of 12 weeks.
What immediate relief methods are available for frequent hot flashes?During sudden hot flashes, deep breathing relaxation techniques or cold compresses on the neck vessels can be used immediately. Daily clothing strategies include wearing layered, easily removable clothing, and avoiding caffeine and hot foods that trigger symptoms. Doctors also recommend daily intake of vitamin B complex and magnesium, which may help regulate autonomic nervous system sensitivity.
How often should bone density be checked for women undergoing long-term treatment?Bone density should be checked every 6 months during the first year of treatment, then annually if bone loss remains stable. Patients on bisphosphonates or with fracture history should have frequency adjusted based on bone turnover markers. Results should be interpreted alongside blood levels of C-terminal telopeptide (CTX) for comprehensive assessment of bone health.
When can psychological symptoms like anxiety or depression improve after treatment?The improvement timeline varies; hormonal therapy typically shows mood stabilization after 4-6 weeks, while anxiolytics may take 2-4 weeks. Combining cognitive-behavioral therapy with medication usually yields noticeable improvements after 8-12 weeks. If symptoms worsen or persist, re-evaluation of the treatment plan is necessary, including potential medication adjustments.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
